Selecione um tamanho
5 MG
R$ 1.510,00
Selecione um tamanho
Alterar visualização
5 MG
R$ 1.510,00
About This Item
Fórmula empírica (Notação de Hill):
C59H83N17O14
Peso molecular:
1254.40
Código UNSPSC:
12352209
NACRES:
NA.32
Produtos recomendados
![[D-Trp6]-LH-RH ≥97% (HPLC), powder](/deepweb/assets/sigmaaldrich/product/structures/321/602/34cc2814-2f6f-4fc9-a266-835bfe27bcc5/640/34cc2814-2f6f-4fc9-a266-835bfe27bcc5.png)
![[D-Lys6]-LH-RH](/deepweb/assets/sigmaaldrich/product/images/327/956/6215aa07-cc81-40f5-97b7-5b2283044678/640/6215aa07-cc81-40f5-97b7-5b2283044678.jpg)
Ensaio
≥95% (HPLC)
Formulário
lyophilized
composição
Peptide Content, ≥72%
condição de armazenamento
protect from light
temperatura de armazenamento
−20°C
Amino Acid Sequence
Glp-His-Trp-Ser-Tyr-Lys-Leu-Arg-Pro-Gly
Aplicação
Luteinizing-hormone-releasing hormone (LHRH) (GnRH) is a decapeptide (pyroQHWSYKLRPG-NH2) trophic hormone that regulates the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary. Various analogues have been developed using D-amino acids to increase resistance to degradation. These analogues are used as potential targeting agents in the development of chemotherapies and as possible agonists and antagonist of the LHRH receptor.
Código de classe de armazenamento
11 - Combustible Solids
Classe de risco de água (WGK)
WGK 3
Ponto de fulgor (°F)
Not applicable
Ponto de fulgor (°C)
Not applicable
Escolha uma das versões mais recentes:
Certificados de análise (COA)
Lot/Batch Number
Não está vendo a versão correta?
Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.
Já possui este produto?
Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.
Andreas R Günthert et al.
Breast cancer research and treatment, 87(3), 255-264 (2004-11-06)
More than 50% of human breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH-R). These receptors can be used for targeted chemotherapy with agents like AN-152, in which doxorubicin is linked to analog [D-Lys6]LHRH. We compared the effects of AN-152
Ana M Bajo et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 9(10 Pt 1), 3742-3748 (2003-09-25)
The receptors for luteinizing hormone-releasing hormone receptor (LHRH-R) are found in >50% of human breast cancers. Doxorubicin (DOX) was linked to [D-Lys(6)]LHRH to form a cytotoxic conjugate, AN-152, which can be targeted to tumor cells expressing LHRH-R. We evaluated the
Alexandra P Kafka et al.
Biomedical chromatography : BMC, 24(2), 132-139 (2009-06-12)
A high-performance liquid chromatography (HPLC) method for assay of d-Lys(6)-GnRH contained in a microemulsion-type formulation is described. The peptide is extracted from the microemulsion matrix and quantified using a two-step gradient method. Separation from microemulsion compounds and potential peptide oxidation
G Emons et al.
European journal of cancer & clinical oncology, 25(2), 215-221 (1989-02-01)
As a first step to investigate whether gonadotropin releasing hormone (GnRH) analogs might be able to modulate directly the proliferation of human epithelial ovarian carcinomata, we checked if binding sites for GnRH are present in these malignancies. Specific binding of
P J Wormald et al.
The Journal of clinical endocrinology and metabolism, 61(6), 1190-1194 (1985-12-01)
A specific, high affinity receptor for GnRH in human pituitaries obtained post mortem is described. The human pituitary GnRH receptor bound GnRH, a GnRH agonist [(D-Ala6,N alpha-MeLeu7,Pro9NEt)-GnRH], and a GnRH antagonist [Ac-D-Nal(2)1,D-alpha-Me-4-ClPhe2,D-3-Pal3,D-Arg6,D-Ala10 )-GnRH] with similar affinities (KdS of 4.81 nM
Active Filters
Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.
Entre em contato com a assistência técnica
